NOVO NORDISK PHARM IND C O K supplier risk profile Q1 2026: Taiwan-heavy pharma imports.
NOVO NORDISK PHARM IND C O K recorded 51 shipments in Q1 2026 across two suppliers and two countries. Taiwan accounted for 96.1% of inbound shipments, dominated by SCANDINAVIAN HEALTH with 49 shipments of medical devices (HS 901831). A secondary source, NOVO NORDISK in Denmark, supplied 2 shipments of pharmaceutical ingredients (HS 293399).
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
No sanctions watchlist matches were identified for this importer in Q1 2026. No suppliers registered forced-labor exposure under UFLPA screening.
2 distinct tier-1 suppliers in Q1 2026
| SCANDINAVIAN HEALTH | Taiwan | 49 |
| NOVO NORDISK | Denmark | 2 |
Share of Q1 2026 inbound shipments by source country
0 tier-2 + 0 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.